Table 3.
Treatment outcome of brachytherapy in circumscribed choroidal hemangiomas in different studies
| Present study | Li et al. [26] | Madreperla et al. [23] | Naseripour et al. [27] | Joshi et al. [28] | Cennamo et al. [8] | Aizman et al. [17] | Lopez-Caballero et al. [3] | Zografos et al. [25] | |
|---|---|---|---|---|---|---|---|---|---|
| Patients, n | 7 | 25 | 8 | 21 | 8 | 7 | 5 | 8 | 41 |
| Isotope | Ru | Ru | Ru and I | Ru | Ru | Ru | Pal | I | Co |
| Mean dose, Gy | 50 | 84.4 | 50 | 38.5 | 32.5 | 100 | 29 | 46.9 | 50 |
| Improved VA, % | 100 | 56 | 63 | 57 | NA | NA | 60 | 0 | NA |
| Mean tumor height, mm | |||||||||
| Baseline | 4.76 | 3.99 | 4.8 | 3.87 | 5.0 | 4.46 | 3.2 | 4.4 | 2.9 |
| Final visit | 1.70 | 0.84 | 2.1 | 0.7 | NA | 2.29 | 1.6 | 1.19 | NA |
| Mean largest diameter, mm | |||||||||
| Baseline | 9.13 | 9.36 | 10.6 | 10.0 | 12.7 | 9.27 | 8.32 | 11.3 | 8.1 |
| Final visit | 4.65 | 7.40 | NA | 8.33 | NA | 4.76 | NA | NA | NA |
| Radiation-related complications, n (%) | |||||||||
| Retinopathy | 0 | 2 (8) | 0 | 5 (23.8) | 0 | NA | 1 (20) | 3 (37.5) | 3 (7.3) |
| Papillopathy | 0 | 0 | 0 | 1 (4.8) | 0 | NA | 0 | 0 | 0 |
| Mean FU, months | 12.5 | 28 | 25 | 38.6 | NA | 12 | 18.6 | 83 | 24–120 |
Co, cobalt-60; I, iodine-125; Pal, palladium-103; Ru, ruthenium-106; VA, visual acuity; FU, follow-up.